Samuelsenlink2560

Side effects due to prostate cancer therapy and psychosocial strain are not always recognised during follow-up, which may result in the absence of appropriate therapy offers. Recent studies have shown apotential for improving care by integrating digital technologies like smartphone apps.

This scoping review aimed to explore the effects of apps for the assessment of side effects and distress, provision of individualised patient information and management of prostate cancer follow-up on patient outcome. Furthermore, findings on user acceptance and recommendations for implementation and evaluation were identified.

The databases MEDLINE, Web of Science, PsycInfo, Cochrane Library, ScienceDirect, PSYNDEX, wiso and SpringerLink were searched for quantitative and qualitative primary studies from the period 2005 until August 2020.

In all, 22studies were included in the review. Apps and web-based interventions had apositive effect on physical symptoms, psychosocial distress and participation in treatment. GDC-1971 mouse User acceptance was predominantly good, but there were still substantial numbers of non-users.

Apps and web-based interventions can be an effective supplement to follow-up care, especially if they are adapted to individual patient needs. Robust evidence is still lacking. There is aneed for larger randomised controlled studies, particularly in the German healthcare setting.

Apps and web-based interventions can be an effective supplement to follow-up care, especially if they are adapted to individual patient needs. Robust evidence is still lacking. There is a need for larger randomised controlled studies, particularly in the German healthcare setting.The representation of the reachable space near the body or peripersonal space (PPS) plays an important role in action with objects and interaction with other people. link2 Here we explored whether the representation of other people's PPS involves a simulation of their action possibility depending on the distance between the observer's body and the other person. We hypothesized that a simulation of action possibilities of others should be activated when they share the PPS of observers. link3 In two experiments using Immersive Virtual Reality, the avatars were shown with their arms free or blocked (motor interference) at a reachable (i.e., Near/shared PPS) or not-reachable (i.e., Far/not-shared PPS) distance by the participants. Participants had to locate a glass in relation to the midline of the avatar's body, i.e., assuming the perspective of the avatar. To directly compare the representation of one's own and others' PPS, in Experiment 1 participants had to locate the glass in relation to themselves with their arms free or blocked. The glass was always within the PPS of either participants or avatars. The results showed that the localization of the glass from the avatar's perspective was slower with the blocked than free arm only when the avatar was in the near shared PPS, similar to the localization from one's own first-person perspective. Instead, there was no effect of motor interference in the far, not-shared PPS. This suggests that the representation of other people's PPS can involve motor simulation mechanisms when we share a common peripersonal area.

While transarterial embolization (TAE) is an effective way to control arterial bleeding associated with pelvic fracture, the clinical outcomes according to door-to-embolization (DTE) time are unclear. This study investigated how DTE time affects outcomes in patients with severe pelvic fracture.

Using a trauma database between November 1, 2015 and December 31, 2019, trauma patients undergoing TAE were retrospectively reviewed. The final study population included 192 patients treated with TAE. The relationships between DTE time and patients' outcomes were evaluated. Multiple binomial logistic regression analyses, multiple linear regression analyses, and Cox hazard proportional regression analyses were performed to estimate the impacts of DTE time on clinical outcomes.

The median DTE time was 150min (interquartile range, 121-184). The mortality rates in the first 24h and overall were 3.7% and 14.6%, respectively. DTE time served as an independent risk factor for mortality in the first 24h (adjusted odds raTAE.

Traditional count-based measures of comorbidity are unlikely to capture the complexity of multiple chronic conditions (multimorbidity) in older adults with cancer. We aimed to define patterns of multimorbidity and their impact in older United States Veterans with multiple myeloma (MM).

We measured 66 chronic conditions in 5,076 Veterans age ≥ 65 years newly-treated for MM in the national Veterans Affairs healthcare system from 2004 to 2017. Latent class analysis (LCA) was used to identify patterns of multimorbidity among these conditions. These patterns were then assessed for their association with overall survival, our primary outcome. Secondary outcomes included emergency department visits and hospitalizations.

Five patterns of multimorbidity emerged from the LCA, and survival varied across these patterns (log-rank two-sided p < .001). Older Veterans with cardiovascular and metabolic disease (30.9%, hazard ratio [HR] = 1.33, 95% confidence interval [CI] = 1.21 to 1.45); psychiatric and substance use disorders (9.7%, HR = 1.58, 95% CI = 1.39 to 1.79); chronic lung disease (15.9%, HR = 1.69, 95% CI = 1.53 to 1.87); and multisystem impairment (13.8%, HR = 2.25, 95% CI = 2.03 to 2.50) had higher mortality compared to Veterans with minimal comorbidity (29.7%, reference). Associations with mortality were maintained after adjustment for socio-demographic variables, measures of disease risk, and the count-based Charlson Comorbidity Index. Multimorbidity patterns were also associated with emergency department visits and hospitalizations.

Our findings demonstrate the need to move beyond count-based measures of comorbidity and consider cancer in the context of multiple chronic conditions.

Our findings demonstrate the need to move beyond count-based measures of comorbidity and consider cancer in the context of multiple chronic conditions.

Even within well studied organisms, many genes lack useful functional annotations. One way to generate such functional information is to infer biological relationships between genes/proteins, using a network of gene coexpression data that includes functional annotations. However, the lack of trustworthy functional annotations can impede the validation of such networks. Hence, there is a need for a principled method to construct gene coexpression networks that capture biological information and are structurally stable even in the absence of functional information.

We introduce the concept of signed distance correlation as a measure of dependency between two variables, and apply it to generate gene coexpression networks. Distance correlation offers a more intuitive approach to network construction than commonly used methods such as Pearson correlation and mutual information. We propose a framework to generate self-consistent networks using signed distance correlation purely from gene expression data, with no additional information. We analyse data from three different organisms to illustrate how networks generated with our method are more stable and capture more biological information compared to networks obtained from Pearson correlation or mutual information.

Supplementary Information and code are available at Bioinformatics and https//github.com/javier-pardodiaz/sdcorGCN online.

Supplementary Information and code are available at Bioinformatics and https//github.com/javier-pardodiaz/sdcorGCN online.

Understanding the impact of the tumor immune microenvironment and BRCA-related DNA repair deficiencies on the clinical activity of immune checkpoint inhibitors may help optimize both patient and treatment selection in metastatic triple-negative breast cancer (mTNBC). In this substudy from the phase 3 IMpassion130 trial, immune biomarkers and BRCA alterations were evaluated for association with clinical benefit with atezolizumab (A) + nab-paclitaxel (nP) vs placebo + nP in unresectable locally advanced or mTNBC.

Patients were randomized 11 to nab-paclitaxel 100 mg/m2 (days 1, 8, and 15 of a 28-day cycle) + atezolizumab 840 mg every 2 weeks or placebo until progression or toxicity. Progression-free survival (PFS) and overall survival (OS) were evaluated based on programmed death-ligand 1 (PD-L1) expression on immune cells (IC) and tumor cells (TC), intratumoral CD8, stromal tumor-infiltrating lymphocytes (sTILs), and BRCA1/2 mutations.

PD-L1 IC+ in either primary or metastatic tumor tissue was linked to PFS and OS benefit with A+nP. PD-L1 IC+ low (26.9%; 243 of 902 patients) and high (13.9%; 125 of 902 patients) populations had improved outcomes that were comparable. Intratumoral CD8 and sTILs positivity were associated with PD-L1 IC+ status; A+nP vs P+nP improved outcomes were observed only in CD8+ and sTIL+ patients who were also PD-L1 IC+. BRCA1/2 mutations (occurring in 14.5% [89 of 612 patients]) were not associated with PD-L1 IC status, and PD-L1 IC+ patients benefited from A+nP regardless of BRCA1/2 mutation status.

Although A+nP was more efficacious in patients with richer tumor immune microenvironment, clinical benefit was only observed in patients whose tumors were PD-L1 IC+.S.

Although A+nP was more efficacious in patients with richer tumor immune microenvironment, clinical benefit was only observed in patients whose tumors were PD-L1 IC+.S.

This study analyses the position of the HeartMate 3 left ventricular assist device on serial radiographs to assess positional change and possible correlation with adverse events.

We retrospectively analysed 59 left ventricular assist device recipients who had serial chest radiographs at 1 month, 6 months and 12 months post-implantation between November 2014 and June 2018. We measured pump angle, pump-spine distance and pump-diaphragm depth and investigated their relationship to a composite outcome of heart failure readmission, low flow alarms, stroke or inflow/outflow occlusion requiring surgical repositioning through recurrent event survival modelling.

Between 1 and 6 months, the absolute pump-spine distance changed by 10.00 mm (P < 0.01) and the absolute pump-diaphragm depth changed by 18.80 mm (P < 0.01). These parameters did not change significantly between 6 and 12 months post-implantation. Pump angle did not change significantly over any period. Twenty-six patients experienced the composite outcome; in these patients, the median 1-month pump angle was 66.2° (interquartile range 54.5-78.0) as compared to 59.0° (interquartile range 47.0-65.0) in the 33 patients who did not have adverse events (P = 0.04). Pump depth and pump-spine distance at 1 month were not associated with the composite outcome. Change in pump depth between 1 and 6 months [hazard ratio (HR) 1.019; 95% confidence interval (CI) 1.000-1.039] and between 6 and 12 months (HR 1.020; 95% CI 1.000-1.040) were weakly associated with the composite outcome.

Larger pump angles are associated with the composite outcome of position-related adverse events. Pump depth movement is weakly associated with the composite outcome.

Larger pump angles are associated with the composite outcome of position-related adverse events. Pump depth movement is weakly associated with the composite outcome.